Related Experiment Videos
[Hepatitis C virus and resulting diseases].
R Armas-Merino1, C Wolff, R Soto
1Departamento de Medicina Occidente, Universidad de Chile.
Revista Medica De Chile
|June 3, 2000
Summary
Hepatitis C virus (HCV) infection, a flavivirus, can lead to chronic liver disease, cirrhosis, and cancer. While transmission is low in Chile, new antiviral drugs offer improved treatment options for this significant global health concern.
Area of Science:
- Virology
- Hepatology
- Infectious Diseases
Context:
- Hepatitis C virus (HCV), a flavivirus, was identified in 1989.
- Reliable laboratory techniques have expanded knowledge of HCV infection and its associated diseases.
- Prevalence and serotype frequency of HCV vary globally, with Chile having a low prevalence.
Purpose:
- To review the current understanding of Hepatitis C virus infection, its clinical manifestations, and treatment modalities.
- To highlight the epidemiological features of HCV in Chile and evolving transmission routes.
- To discuss the impact of HCV on liver and non-liver diseases and the advancements in therapeutic strategies.
Summary:
- HCV infection typically presents as asymptomatic acute hepatitis, with 80% progressing to chronic liver disease, potentially leading to cirrhosis or hepatocellular carcinoma.
- Chronic hepatitis C can mimic autoimmune conditions and is exacerbated by alcohol consumption.
- Associated non-hepatic conditions include essential mixed cryoglobulinemia, glomerulonephritis, porphyria cutanea tarda, and type 2 diabetes mellitus.
Impact:
- Improved blood screening has reduced HCV transmission via transfusion.
- Intravenous drug use, hemodialysis, and transplantation are increasingly recognized as significant transmission routes.
- While interferon-based therapies offer limited success, new antiviral drugs and liver transplantation represent crucial advancements in managing severe HCV disease and improving patient prognosis.